Immunotherapy for cancer in the central nervous system: Current and future directions
about
Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System MalignanciesSingle vs. combination immunotherapeutic strategies for glioma.High expression of B7-H6 in human glioma tissues promotes tumor progressionDendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis.Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival.Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls.RBM5 inhibits tumorigenesis of gliomas through inhibition of Wnt/β-catenin signaling and induction of apoptosis.Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade.miR-15b Inhibits the Progression of Glioblastoma Cells Through Targeting Insulin-like Growth Factor Receptor 1.Immune Checkpoint Inhibitors in Gliomas.MicroRNA-206 Inhibited the Progression of Glioblastoma Through BCL-2.Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.The Kynurenine/Tryptophan Ratio and Glioblastoma Patients Treated with Hsppc-96 Vaccine.Improving vaccine efficacy against malignant gliomaGlioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.Guidelines for the use of flow cytometry and cell sorting in immunological studies.Updates from the Neuro-Oncology Section of the 2015 American Neurological Association Annual Meeting.Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma.Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.MicroRNA‑376a inhibits cell proliferation and invasion in glioblastoma multiforme by directly targeting specificity protein 1.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma.Nuclear Smad6 promotes gliomagenesis by negatively regulating PIAS3-mediated STAT3 inhibition.Glioblastoma Treatments: An Account of Recent Industrial DevelopmentsLncRNA UCA1 is necessary for TGF-β-induced epithelial-mesenchymal transition and stemness via acting as a ceRNA for Slug in glioma cellsBlockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy
P2860
Q28072007-BADFFA90-F884-4DD4-A1B6-99D264E3082DQ33746041-1B6C73EA-4B9C-497B-848E-C8099AC3FFD5Q33913978-515D5E54-DBA1-4FFC-9072-4563002EBD58Q36201736-C23C856D-5447-42E9-9F04-F9A7176AFAA8Q36276257-47A7B076-E899-4A51-8382-04E87D47F887Q37125964-E5364419-7A96-4606-98E5-F6E8129CE197Q37569674-F98D8158-B5E7-4B59-A6E1-5F5576BBEA56Q38691679-2D272EFB-70D9-4803-8BC5-F7C0D6F2485EQ38728456-499375CE-C599-432B-A62E-90B5668A4B2DQ38743793-22E128FC-92F7-47DE-AF58-FAEBB6B7D579Q38750345-77B62173-17D3-4180-943C-1C0ED366D8C3Q38759702-F8BD90C4-9C7B-4929-9939-91B978027A6CQ38797946-289EA82C-AB4E-4690-92CC-7856EFA649A5Q38953024-B7E7D959-547E-4396-973F-B339E9789BCAQ39196377-CCD13E19-97DA-42D5-871E-1AC450C5AD83Q41918189-6E383F36-C357-451E-9CFC-BD87F99BE5F5Q42554908-1F0F8C87-6F8C-4A96-8ADB-16C6D70A326CQ42639856-884E9A5D-24AF-4DCC-A019-8EA397611C20Q42778369-DB8FB7BD-3349-4899-9E71-BEBBCF517B33Q47141309-451B27E7-20EB-4E29-96EA-AA8C837271AFQ47276495-EF52DD40-FC03-4C7B-89AA-6AAF164E01E2Q47325431-437DEDF1-488B-4317-ABE6-C5401BB83A77Q47828100-F41F9DD3-9C13-4EA6-A2FA-AA6AB2B15A2BQ47996105-6CB267D6-337C-41A7-9F2F-1A5132D52F58Q55363685-2701F908-BE05-4935-9F45-8F4B4AB447D7Q57111067-B79EE6BE-3E08-46C6-8676-5550068ED75DQ58595858-CCD93F65-12A1-4372-8BDB-90A702D1395EQ59129078-DAB550B5-63DE-4511-891E-9B9E5CCD27C5
P2860
Immunotherapy for cancer in the central nervous system: Current and future directions
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Immunotherapy for cancer in the central nervous system: Current and future directions
@ast
Immunotherapy for cancer in the central nervous system: Current and future directions
@en
Immunotherapy for cancer in the central nervous system: Current and future directions
@nl
type
label
Immunotherapy for cancer in the central nervous system: Current and future directions
@ast
Immunotherapy for cancer in the central nervous system: Current and future directions
@en
Immunotherapy for cancer in the central nervous system: Current and future directions
@nl
prefLabel
Immunotherapy for cancer in the central nervous system: Current and future directions
@ast
Immunotherapy for cancer in the central nervous system: Current and future directions
@en
Immunotherapy for cancer in the central nervous system: Current and future directions
@nl
P2860
P3181
P1433
P1476
Immunotherapy for cancer in the central nervous system: Current and future directions
@en
P2093
Andrew A Davis
David C Binder
P2860
P304
P3181
P356
10.1080/2162402X.2015.1082027
P577
2015-09-11T00:00:00Z